Blueprint inks deal to buy lung cancer biotech LengoTargeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and Share XBlueprint inks deal to buy lung cancer biotech Lengohttps://pharmaphorum.com/news/blueprint-inks-deal-to-buy-lung-cancer-biotech-lengo/
After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerEli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced Share XAfter Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerhttps://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/
Roche, Blueprint’s RET cancer drug Gavreto cleared in EURoche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, Share XRoche, Blueprint’s RET cancer drug Gavreto cleared in EUhttps://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/
Blueprint’s latest approval for Ayvakit sets up clash with NovartisBlueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), Share XBlueprint’s latest approval for Ayvakit sets up clash with Novartishttps://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
Roche, Blueprint raise pressure on Lilly with new Gavreto approvalThe FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting Share XRoche, Blueprint raise pressure on Lilly with new Gavreto approvalhttps://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/
Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drugCancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that Share XBlueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drughttps://pharmaphorum.com/news/blueprint-and-roche-take-on-lilly-as-fda-approves-ret-targeting-lung-cancer-drug/
European regulators back Blueprint’s Ayvakyt for stomach tumoursEuropean regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain Share XEuropean regulators back Blueprint’s Ayvakyt for stomach tumourshttps://pharmaphorum.com/news/european-regulators-back-blueprints-ayvakyt-for-stomach-tumours/
Roche signs $1.7bn deal with Blueprint around cancer drug pralsetinibRoche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that Share XRoche signs $1.7bn deal with Blueprint around cancer drug pralsetinibhttps://pharmaphorum.com/news/roche-signs-1-7bn-deal-with-blueprint-around-cancer-drug-pralsetinib/
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gastrointestinal stromal tumour – Share XBlueprint pays the price of Ayvakit phase 3 miss as FDA rejects drughttps://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/
